Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Review

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

Authors: Yun-Jian Sheng, Jun-Ying Liu, Shi-Wen Tong, Huai-Dong Hu, Da-Zhi Zhang, Peng Hu, Hong Ren

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Background

Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance.

Methods

We searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks (RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences (SMD) in HBV DNA levels and safety were reviewed.

Results

Six eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic response. Additionally, combination therapy or monotherapy were both well tolerated.

Conclusions

LAM plus ADV combination therapy was more effective and produced longer-lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections.
Appendix
Available only for authorised users
Literature
1.
Cao GW: Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009,15(46):5761-5769. 10.3748/wjg.15.5761PubMedCentralCrossRefPubMed
2.
Ganem D, Prince AM: Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004,350(11):1118-1129. 10.1056/NEJMra031087CrossRefPubMed
3.
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006,295(1):65-73. 10.1001/jama.295.1.65CrossRefPubMed
4.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006,130(3):678-686. 10.1053/j.gastro.2005.11.016CrossRefPubMed
5.
Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008,134(2):405-415. 10.1053/j.gastro.2007.11.036PubMedCentralCrossRefPubMed
6.
Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P: Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis. Virol J 2011, 8: 72. 10.1186/1743-422X-8-72PubMedCentralCrossRefPubMed
7.
Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009,16(4):265-271. 10.1111/j.1365-2893.2009.01070.xCrossRefPubMed
8.
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003,36(6):687-696. 10.1086/368083CrossRefPubMed
9.
10.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006,131(6):1743-1751. 10.1053/j.gastro.2006.09.020CrossRefPubMed
11.
Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008,48(3):750-758. 10.1002/hep.22414CrossRefPubMed
12.
Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A: Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008,48(4):540-547. 10.1016/j.jhep.2007.12.018CrossRefPubMed
13.
Chen EQ, Wang LC, Lei J, Xu L, Tang H: Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009, 6: 163. 10.1186/1743-422X-6-163PubMedCentralCrossRefPubMed
14.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006,354(10):1011-1020. 10.1056/NEJMoa051287CrossRefPubMed
15.
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007,133(5):1437-1444. 10.1053/j.gastro.2007.08.025CrossRefPubMed
16.
Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009,49(1):72-79. 10.1002/hep.22658CrossRefPubMed
17.
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009,49(5):1503-1514. 10.1002/hep.22841CrossRefPubMed
18.
Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009,50(3):661-662. 10.1002/hep.23190CrossRefPubMed
19.
Pawlotsky JM: EASL Clinical Practice Guidelines. J Hepatol 2009,50(2):243.. 10.1016/j.jhep.2008.11.012CrossRefPubMed
20.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996,17(1):1-12. 10.1016/0197-2456(95)00134-4CrossRefPubMed
21.
Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG, Kim YJ, Yoon JH, Lee HS: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Dig Dis Sci 2011 Jul,56(7):2130-2136. 10.1007/s10620-010-1561-2CrossRef
22.
Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY: Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010,82(11):1835-1842. 10.1002/jmv.21898CrossRefPubMed
23.
Qiu YW, Jiang XH, Huang LH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M: [A study on the treatment of chronic hepatitis B with YMDD mutation]. Zhonghua Gan Zang Bing Za Zhi 2009,17(3):171-174.PubMed
24.
Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI: Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010,25(8):1374-1380. 10.1111/j.1440-1746.2010.06381.xCrossRefPubMed
25.
Pellicelli AM, Barbarini G, Romano M, Furlan C, Paffetti A, Villani R, D'Ambrosio C, Guarascio P, Cerasari G, Fondacaro L, Mazzoni E, Barlattani A, Mecenate F, Nosotti L, Puoti C, Morrone A, Gentilucci UV, Picardi A, Lusi AE, Andreoli A, Soccorsi F: Entecavir therapy for Lamivudine resistant HBV cirrhotic patients waiting for olt: Viral and biochemical outcomes at one year. Hepatology 2009,50(SUPPL.4):514A.
26.
Lee HW, Kim HJ, Choi CH, Do JH, Chang SK: Entecavir rescue therapy versus adefovir combination therapy in lamivudine-refractory patients with chronic hepatitis B. Hepatology International 2010,4(1):132-133.
27.
Yim HJ, Seo YS, Kim JH, Kim CW, Lee CD, Park SH, Lee MS, Park CKN, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Il Lee J, Um SH: Adding adefovir compared with switching to entecavir in paients with lamivudine-resistant chonic heaptitis B (ACE STUDY) - a multicenter prospective randomized study: one-year interim analysis. Hepatology 2010,52(SUPPL.4):560A.
28.
Jang E, Lee J, Yoon J, Cho E, Yang H, Kwak M, Ahn D, Hwang S, Yu S, Lee C, Kim Y, Lee H: The comparison of three rescue treatment strategies for lamivudine-resistant chronic hepatitis B: lamivudine and adefovir combination therap, entecavir monotherapy, and adefovir monotherapy. Hepatology 2010,52(SUPPL 4):520A.
29.
Liaw YF: Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006,11(6):669-679.PubMed
30.
31.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008,48(1):99-108. 10.1002/hep.22323CrossRefPubMed
32.
Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H: Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008,23(9):1320-1326. 10.1111/j.1440-1746.2008.05455.xCrossRefPubMed
33.
Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004,48(9):3498-3507. 10.1128/AAC.48.9.3498-3507.2004PubMedCentralCrossRefPubMed
34.
Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F: Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007,46(3):531-538. 10.1016/j.jhep.2006.11.016CrossRefPubMed
35.
Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007,133(5):1445-1451. 10.1053/j.gastro.2007.08.079CrossRefPubMed
36.
Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007,45(2):307-313. 10.1002/hep.21534CrossRefPubMed
37.
Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H: Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008,48(6):923-931. 10.1016/j.jhep.2008.02.019CrossRefPubMed
38.
Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010,53(3):449-454. 10.1016/j.jhep.2010.03.020CrossRefPubMed
39.
Ryu H, Lee JM, Ahn SH, Kim DY, Lee KS, Han K-H, Chon CY, Moon YM, Park JY: Comparision of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV. Hepatology International 2010.,4(1): 1(165)
40.
Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008,48(5):747-755. 10.1016/j.jhep.2008.01.027CrossRefPubMed
41.
Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, Botta D, Thibault V, Khiri H, Tamalet C: Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006,11(8):1103-1106.PubMed
42.
Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM: Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009,49(1):50-59. 10.1002/hep.22634PubMedCentralCrossRefPubMed
43.
Vigano M, Lampertico P, Iavarone M: High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. J Hepatol 2009, 50: S338-339.CrossRef
Metadata
Title
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
Authors
Yun-Jian Sheng
Jun-Ying Liu
Shi-Wen Tong
Huai-Dong Hu
Da-Zhi Zhang
Peng Hu
Hong Ren
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-393

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue

Research

Novel sequences of subgroup J avian leukosis viruses associated with hemangioma in Chinese layer hens

Research

Diversity and phylogeography of begomovirus-associated beta satellites of okra in India

Research

Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications

Research

Hepatitis B virus induces G1 phase arrest by regulating cell cycle genes in HepG2.2.15 cells

Short report

Long-term respiratory follow-up of H1N1 infection

Research

Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits